HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

CPTS: CONCEPTUS INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CONCEPTUS INC (NASD)
CPTS 13.45 -0.09 (-0.66%) Vol.  83,873 15:09 ET

Zacks Rank: 5 - Strong Sell

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 13.15 - 13.54
52wk Low - High 9.68 - 15.70
Avg Volume 173,766
Industry MED PRODUCTS
Market Cap 422.99 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -.01
EPS Last Year -0.03
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
5 - Strong Sell
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 01/23/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CONCEPTUS INC CPTS 5
SYNOVIS LIF TEC SYNO 1
OMEROS CORP OMER 1
CHEMBIO DIAGNOS CEMI 2
Top Peer Analysis Zacks Premium
See all MED PRODUCTS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.00
ABR (Last Week) 2.00
# of Recs in ABR 11
Average Target Price 14.22
Rank in Industry 49 out of 77
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate CPTS?
Buy
Sell
Find out what the Zacks Community
thinks of CPTS at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR CPTS
Zacks Blog: Hologic Tops Estimates
Jan 31, 2012
Zacks Equity Research: Report for CPTS
Jan 23, 2012
Zacks Blog: Several Setbacks for Conceptus
Jan 10, 2012
Zacks Blog: Zacks #5 Rank Additions for Tuesday
Dec 27, 2011
Zacks Blog: Conceptus Lowers 2011 Guidance
Dec 09, 2011
Zacks Blog: Hologic Launches C-View Software
Nov 29, 2011
Zacks Blog: Hologic Remains Neutral
Nov 17, 2011
Zacks Blog: CPTS' Essure In Sync with Novasure
Nov 11, 2011
More Zacks Commentary
NEWS
Barrington`s Best Stock Picks for 2012 - TheStreet.com
Jan 12, 2012
Conceptus Appoints D. Keith Grossman President and Chief Executive Officer - Benzinga
Dec 08, 2011
Conceptus Expects 2011 Net Sales $126-$128M vs $132M Est - Benzinga
Dec 08, 2011
Conceptus(R) Receives FDA Approvable Letter for Compatible Use of Hologic`s NovaSure With Essure Inserts in Place - Benzinga
Nov 08, 2011
Barrington Research Maintains Outperform Rating and $20 PT on Conceptus - Benzinga
Oct 27, 2011
Barrington Reiterates Outperform Rating and $20 PT on Conceptus - Benzinga
Oct 18, 2011
Conceptus Acquires All Distribution Rights Related to the Essure Procedure in the Netherlands - Benzinga
Oct 04, 2011
Conceptus Enters Into New Revolving Line of Credit Agreement With Wells Fargo Bank - Benzinga
Aug 26, 2011
More News
EARNINGS ESTIMATES
  This Quarter
12/2011
Next Quarter
03/2012
This Year
12/2011
Next Year
12/2012
Average Estimate -0.02 -0.09 -0.19 -0.01
Number of Estimates 10 9 10 10
Low Estimates -0.11 -0.22 -0.28 -0.45
High Estimate 0.10 -0.02 -0.07 0.27
Year Ago EPS 0.14 -0.09 0.10 -0.19
EPS Growth -111.43% -2.47% -286.00% 93.01%

More Estimates

COMPANY DESCRIPTION
Conceptus, Inc. designs and develops minimally invasive devices for reproductive medical applications. Conceptus' focus is to develop its STOP non-surgical permanent contraception device for women. STOP is designed to be a less-invasive, safer, and less costly alternative to surgical sterilization, more commonly known as tubal ligation. The STOP device is designed to achieve contraception by elliciting a tissue response which occludes the fallopian tubes.

Full Company Report
FINANCIALS
EPS TTM -.03
Sales 140.66
Net Income 78.28
Price/Earnings N/A
Price/Book 2.78
Price/Cash Flow 24.41
Price/Sales 3.25


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research